The Role of DEF and SSU Processome in Neuroblastoma Pathogenesis |
Dana-Farber Cancer Institute / Ting Tao, PhD |
Young Investigator Grants |
2015 |
Massachusetts |
Regulation of Tumor Debris Mediated Inflammation as a Therapeutic Modality in Medulloblastoma |
Dana-Farber Cancer Institute / Mark Kieran, MD, PhD & Dipak Panigrahy, MD |
Innovation Grants |
2015 |
Massachusetts |
The Role of PARP3 in the Formation of Chromosomal Translocations |
Dana-Farber Cancer Institute / Tovah Day, PhD |
Young Investigator Grants |
2015 |
Massachusetts |
Therapeutic Reactivation of p53 to Overcome Apoptotic Resistance in Pediatric Leukemia |
Dana-Farber Cancer Institute / Loren Walensky, MD, PhD & Kimberly Stegmaier, MD |
Reach Grants |
2015 |
Massachusetts |
Identifying Epigenetic Mechanisms Impacting Neuroblastoma Genome Stability and Drug Response |
Massachusetts General Hospital / Johnathan Whetstine, PhD |
Innovation Grants |
2015 |
Massachusetts |
Characterizing Resistance Mechanisms to BET-Bromodomain Inhibition in MYC-amplified |
Broad Institute / Rameen Beroukhim, MD,PhD |
Innovation Grants |
2015 |
Massachusetts |
Identifying Mechanisms of Glucocorticoid Resistance in Pediatric Acute Lymphoblastic |
University of Massachusetts Medical School / Michelle Kelliher, PhD |
Innovation Grants |
2015 |
Massachusetts |
Novel Nanoscale Phosphoproteomic Discovery of Therapeutic Targets in AML Stem Cells |
Dana-Farber Cancer Institute / Leo Wang, MD, PhD |
Young Investigator Grants |
2015 |
Massachusetts |
Elucidating Mechanisms Driving Renal Medullary Carcinomas to Deliver a Rational Approach to Cancer
Directed Therapy
|
Dana-Farber Cancer Institute / Andrew Hong, MD |
Young Investigator Grants |
2015 |
Massachusetts |
A Translational Approach to Identify Drugs with Specific Activity Against EZH2 Mutant High Risk T-ALLs and ETP ALLs that Overexpress the JDP2 bZIP Transcription Factor |
Dana-Farber Cancer Institute / Shuning He, PhD |
Young Investigator Grants |
2015 |
Massachusetts |